Approval Pathways 5211.1 Biobetter Therapies 5211.2 Biosimilar Therapies 5212 India Regulatory Environment and Approval Pathways 5312.1 Biobetter Therapies 5312.2 Biosimilar Therapies 5313 Biobetter Companies 5413.1 Key Players 5413.1.1 Amgen 5413.1.2 SWOT Analysis 5513.1.3 Merck 5613.1.4 SWOT Analysis 5613.1.5 Roche 5713.1.6 SWOT Analysis 5813.1.7 Novo Nordisk 5913.1.8 SWOT Analysis 5913.1.9 Sanofi-Aventis 6013.1.10 SWOT Analysis 6114 Strategic Consolidations 6214.1 Deals Analysis 6214.1.1 Mergers and Acquisitions 6214.1.2 Licensing Agreements 6915 Biobetters Therapeutics Market to 2018 - Appendix 7615.1 Abbreviations 7615.2 Sources 7815.3 Research Methodology 7815.3.1 Coverage 7915.3.2 Secondary Research 7915.3.3 Primary Research 7915.3.4 Forecasts 8015.3.5 Expert Panel Validation 8215.4 Contact Us 8215.5 Disclaimer 82
List of Tables
1.1 List of TablesTable 1: Biobetters in Key Markets, Human Growth Hormone Therapeutics Pipeline, Development-stage Molecules, 2012 33Table 2: Biobetters in Key Markets, Erythropoietin Pipeline, Development-stage Molecules, 2012 34Table 3: Biobetters in Key Markets, Granulocyte-colony Stimulating Factor Pipeline, Development-stage Molecules, 2012 35Table 4: Biobetters in Key Markets, Interferon-? and ? Pipeline, Development-stage Molecules, 2012 37Table 5: Biobetters in Key Markets, Insulin Pipeline, Development-stage Molecules, 2012 39Table 6: Biobetters in Key Markets, Monoclonal Antibodies Pipeline, Development-stage Molecules, 2012 40Table 7: Biobetters in Key Markets, Monoclonal Antibodies Pipeline, Development-stage Molecules, 2012 (Contd.) 41
List of Figures
1.2 List of FiguresFigure 1: Biobetters in Key Markets, Erythropoietin, Global, Revenue Sales ($m), 2000-2011 13Figure 2: Biobetters in Key Markets, Granulocyte-colony Stimulating Factor, Global, Revenue Sales ($m), 2000-2011 14Figure 3: Biobetters in Key Markets, Interferon-alpha, Global, Revenue Sales ($m), 2000-2011 16Figure 4: Biobetters in
'/>"/>
SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related biology technology :1.
AspenBio to Present at 2012 Lazard Capital Markets Healthcare Conference2.
Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference3.
Regulus to Present at the Lazard Capital Markets Healthcare Conference4.
PDL BioPharma to Present at the Lazard Capital Markets 9th Annual Healthcare Conference5.
Tengion to Present at the Lazard Capital Markets 9th Annual Healthcare Conference6.
Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference7.
MiMedx Group to Present at the BIOX; Noble Financial Capital Markets Life Sciences Exposition8.
Kinase Inhibitors: Global Markets -- Focus on the U.S.9.
MarketsandMarkets: Global Refurbished Medical Equipments Market worth $8.45 Billion by 201710.
MarketsandMarkets: Global Spine Surgery Devices Market Worth $14.8 Billion by 201711.
MarketsandMarkets: World Sensors Market in Healthcare Applications is expected to reach $13.11 billion by 2017